Plasma IL8 Is a Biomarker for TAK1 Activation and Predicts Resistance to Nanoliposomal Irinotecan in Patients with Gemcitabine-Refractory Pancreatic Cancer.
Valeria MerzCamilla ZecchettoRaffaela SantoroFrancesca SimionatoFabio SabbadiniDomenico MangiameliGeny PiroAlessandro CavaliereMichela DeianaMaria Teresa ValentiDiana BazanVita FedeleSara LonardiDavide MelisiPublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2020)
Our study identified IL8 as the most significant circulating factor for TAK1 pathway activation and candidates IL8 as a potential predictive biomarker of resistance to nal-IRI in gemcitabine-refractory patients with pancreatic cancer.
Keyphrases